Wacker’s Biotechnology Center uses bioreactors with sizes ranging from a few milliliters to pilot reactors with a capacity of 200 liters.
Situated in Munich’s Sendling quarter, a research hub for over a century, the center enhances Wacker’s biotechnology focus. CEO Christian Hartel said: “The WACKER Biotech Center will allow us to concentrate and intensify our biotech research activities. We see tremendous growth potential in this area, which is why we have decided to go ahead and invest in this sector – even in economically challenging times.” Bavarian Minister Hubert Aiwanger stated: “With the new Biotechnology Center, WACKER is not only securing high-quality jobs, but also strengthening Bavaria’s expertise in biotechnology. This demonstrates a strong commitment to Bavaria as a business location, and is exactly the kind of project we need to ensure our competitiveness and bring innovations from Bavaria to the world.”
Spanning four floors with 1,500 square meters of labs and 700 square meters of offices, the center supports 90 employees. Its bioreactors, ranging from milliliters to 200 liters, enable research into biopharmaceuticals like mRNA therapies and sustainable food ingredients.
Hartel noted: “It is no longer enough to simply have the best solution. It’s becoming increasingly important that we reach the customer with this solution first. Speed is taking on an ever greater role in making us stand out.” The center improves efficiency and collaboration with customers and Biosolutions, accelerating product development.
The facility bolsters Munich’s biotechnology hub status, driving sustainable innovation and economic growth in Bavaria.
